Contributions
Abstract: P1207
Type: Poster
Abstract Category: Therapy - disease modifying - Neuroprotection
Background: Post-hoc analyses of data from pivotal clinical trials have suggested that natalizumab may stabilise neurological functioning and slow disability progression in people with multiple sclerosis, as measured by the Expanded Disability Status Scale.
Aim: To determine real-world effectiveness of natalizumab on physical functioning, using:
1. Long-term serial observations from a large cohort of patients monitored at the Greater Manchester Neurosciences Centre, UK.
2. Nine hole peg test (9HPT) and timed 25 metre walk (T25MW) data as meaningful markers of upper and lower limb functioning.
Methods: All patients in Greater Manchester receiving treatment with natalizumab for ≥2years were included for analysis (N=160). Patients undergo 9HPT and T25MW every 4 weeks before their elective natalizumab infusion. Data was analysed up to the end of October 2015.
Results: Mean T25MW dropped notably from 31.1 at baseline to 24.1 seconds (-22.5%) after 4 weeks, an improvement sustained for 24 months (23.9s). 9HPT measures initially fluctuated but similarly improved in both right (26.9 to 22.2s; -17.5%) and left (29.0 to 24.4s; -15.9%) hands. Considering attrition in numbers, there was no significant deterioration in function in patients who continued on treatment for 48 months (N=74; T25MW 22.0s; (R)9HPT 20.4s; (L)9HPT 21.7s), 60 months (N=52; T25MW 20.2s; (R)9HPT 23.3s; (L)9HPT 25.4s) and 72 months (N=29; T25MW 20.1s; (R)9HPT 22.6s; (L)9HPT 24.5s).
Conclusion: Serial data from clinical practice provide valuable additional evidence that natalizumab protects neurological performance, as quantified by two clinically meaningful measures of limb function, for up to 6 years of treatment.
Disclosure: Adrian Pace: nothing to declare
William Lusher: nothing to declare
Tatiana Mihalova: nothing to declare
Nazar Sharaf: nothing to declare
Paul Talbot: nothing to declare
David Rog: nothing to declare
Abstract: P1207
Type: Poster
Abstract Category: Therapy - disease modifying - Neuroprotection
Background: Post-hoc analyses of data from pivotal clinical trials have suggested that natalizumab may stabilise neurological functioning and slow disability progression in people with multiple sclerosis, as measured by the Expanded Disability Status Scale.
Aim: To determine real-world effectiveness of natalizumab on physical functioning, using:
1. Long-term serial observations from a large cohort of patients monitored at the Greater Manchester Neurosciences Centre, UK.
2. Nine hole peg test (9HPT) and timed 25 metre walk (T25MW) data as meaningful markers of upper and lower limb functioning.
Methods: All patients in Greater Manchester receiving treatment with natalizumab for ≥2years were included for analysis (N=160). Patients undergo 9HPT and T25MW every 4 weeks before their elective natalizumab infusion. Data was analysed up to the end of October 2015.
Results: Mean T25MW dropped notably from 31.1 at baseline to 24.1 seconds (-22.5%) after 4 weeks, an improvement sustained for 24 months (23.9s). 9HPT measures initially fluctuated but similarly improved in both right (26.9 to 22.2s; -17.5%) and left (29.0 to 24.4s; -15.9%) hands. Considering attrition in numbers, there was no significant deterioration in function in patients who continued on treatment for 48 months (N=74; T25MW 22.0s; (R)9HPT 20.4s; (L)9HPT 21.7s), 60 months (N=52; T25MW 20.2s; (R)9HPT 23.3s; (L)9HPT 25.4s) and 72 months (N=29; T25MW 20.1s; (R)9HPT 22.6s; (L)9HPT 24.5s).
Conclusion: Serial data from clinical practice provide valuable additional evidence that natalizumab protects neurological performance, as quantified by two clinically meaningful measures of limb function, for up to 6 years of treatment.
Disclosure: Adrian Pace: nothing to declare
William Lusher: nothing to declare
Tatiana Mihalova: nothing to declare
Nazar Sharaf: nothing to declare
Paul Talbot: nothing to declare
David Rog: nothing to declare